Arrowhead Pharmaceuticals Inc (ARWR)

Debt-to-assets ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	393,183	—	—	—	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total assets	US$ in thousands	1,139,800	883,759	955,150	626,286	765,552	795,856	891,308	891,489	691,939	751,782	703,575	638,539	710,148	734,927	756,795	499,251	522,504	555,728	561,076	587,602
Debt-to-assets ratio		0.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

September 30, 2024 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $393,183K ÷ $1,139,800K
= 0.34

The debt-to-assets ratio of Arrowhead Pharmaceuticals Inc has fluctuated over the periods indicated. As of September 30, 2024, the debt-to-assets ratio was 0.34, indicating that the company had a level of debt relative to its total assets. However, in the previous quarters, the ratio was 0.00, suggesting that the company either had no debt or a negligible amount of debt in relation to its assets during those periods.

It is important to consider the reasons behind the significant increase in the debt-to-assets ratio in the most recent period and monitor how this trend evolves in subsequent quarters. A higher debt-to-assets ratio could indicate increased leverage and financial risk for the company, as more of its assets are financed by debt. Conversely, a lower ratio suggests a healthier financial position with less reliance on debt financing.

Further analysis of the composition and terms of the debt, as well as the company's overall financial health and performance, would provide additional insights into the implications of the debt-to-assets ratio for Arrowhead Pharmaceuticals Inc.